A novel supramolecular lipid nanoparticle (SMLNP) delivery platform has been developed, consisting of an ionizable lipid (N2-3L) for delivering tumor antigen mRNA, and a β-cyclodextrin (β-CD)-modified ionizable lipid (Lip-CD) for encapsulating the Toll-like receptor 7/8 (TLR7/8) agonist R848. The combination of the mRNA vaccine and R848 significantly enhanced dendritic cell maturation and antigen presentation, resulting in superior antitumor efficacy in vivo.
1 mg (N-1034)
A novel supramolecular lipid nanoparticle (SMLNP) delivery platform has been developed, consisting of an ionizable lipid (N2-3L) for delivering tumor antigen mRNA, and a β-cyclodextrin (β-CD)-modified ionizable lipid (Lip-CD) for encapsulating the Toll-like receptor 7/8 (TLR7/8) agonist R848. [Read More...]
$75
